Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 3 3Phase 2 3Phase 1/2 3

Status

Active not recruiting 5Completed 3Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1

Conditions

Multiple Myeloma 3Paraproteinemias 1Neoplasms 1Lymphoproliferative Disorders 1Immunoproliferative Disorders 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Completed × isatuximab × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT03275285 2026-02-09

IKEMA

Sanofi

Phase 3 Completed
302 enrolled 38 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Sanofi

Phase 3 Completed
307 enrolled 32 charts 1 FDA
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡